Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: diphenhydramine Clear all
Recruiting Phase 4 Interventional

A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia

NCT07542756
View directory record Official record
Conditions
Insomnia, Insomnia Disorder, Chronic Insomnia, Chronic Insomnia Disorder
Interventions
Sleep Hygiene Education, Melatonin IR, 3 mg, Melatonin IR, 5 mg, Diphenhydramine, 25 mg, Diphenhydramine, 50 mg, Doxepin, 3 mg, Doxepin, 6 mg, Trazodone, 50 mg, Trazodone, 100 mg, Placebo, Zolpidem, 5 mg, Zolpidem, 10 mg
Other · Dietary Supplement · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 4 Interventional

The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant

NCT00275639
View directory record Official record
Conditions
Liver Transplant Recipients
Interventions
Cozaar
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 4 Interventional Results available

Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine

NCT01118273
View directory record Official record
Conditions
Sleep
Interventions
Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg, Naproxen Sodium 440 mg (BAYH6689), Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg, Naproxen Sodium 220 mg (BAYH6689), DPH 50mg, Ibuprofen 400 mg / Diphenhydramine citrate 76 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 2 Interventional

Improving Outcomes in Patients With Kidney Disease Due to Diabetes

NCT00381134
View directory record Official record
Conditions
Diabetes, Kidney Disease, Hypertension
Interventions
losartan 100 mg orally once daily, spironolactone 25 mg orally once daily, placebo once orally once daily
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 25, 2026, 10:22 PM EDT
Recruiting Phase 1 Interventional

The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)

NCT06070649
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Alcohol-Related Disorders, Alcohol Use
Interventions
0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion, 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion, 25 mg Diphenhydramine (5 min) + Normal Saline
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 4 Interventional Results available

Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients

NCT02188121
View directory record Official record
Conditions
Serious Mental Illness, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Cardiovascular Disease, Major Depressive Disorder, Psychosis NOS
Interventions
Simvastatin, Losartan
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 89 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 25, 2026, 10:22 PM EDT
Terminated No phase listed Observational

Pain Study to See if Ultram ER Will Provide Relief to Subjects Whose Pain is Not Well Controlled by Narcotics

NCT00505531
View directory record Official record
Conditions
Chronic Pain
Interventions
Tramadol Extended Release Oral Capsule, Benadryl
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 4 Interventional Results available

Alternative Sedation During Bronchoscopy

NCT01158820
View directory record Official record
Conditions
Sedation
Interventions
Dexmedetomidine load, Ketamine load, Midazolam load, Fentanyl load, Dexmedetomidine maintenance, Ketamine maintenance, Midazolam demand, Fentanyl demand, Benadryl demand
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 4 Interventional Results available

Metoclopramide Versus Ketorolac for Tension-type Headache

NCT01011673
View directory record Official record
Conditions
Headache
Interventions
Metoclopramide, Ketorolac
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 3 Interventional

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension

NCT00095394
View directory record Official record
Conditions
Hypertension
Interventions
Irbesartan/HCTZ, Irbesartan monotherapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
156
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 153 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Drug-drug Interaction Study in Healthy Volunteers

NCT02227173
View directory record Official record
Conditions
Drug-drug Interaction Study
Interventions
BMS-986020, Montelukast, Flurbiprofen, Digoxin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

Losartan for Patients With COVID-19 Not Requiring Hospitalization

NCT04311177
View directory record Official record
Conditions
Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
Interventions
Losartan, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction

NCT02474199
View directory record Official record
Conditions
Liver Transplant Recipient, Living Donor (of the Respective Liver Transplant Recipient)
Interventions
darTregs, Acetaminophen, Diphenhydramine, Immunosuppression (IS) Withdrawal, Study Mandated Procedures
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treating the Endothelium to Restore Insulin Sensitivity

NCT00402194
View directory record Official record
Conditions
Obesity, Insulin Resistance, Impaired Glucose Tolerance, Pre-diabetes
Interventions
Losartan
Drug
Lead sponsor
Indiana University
Other
Eligibility
20 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis

NCT01048866
View directory record Official record
Conditions
Pharyngitis
Interventions
placebo, flurbiprofen, acetaminophen 650mg
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Topical Acetaminophen for Itch Relief: a Proof of Concept Study in Healthy Subjects

NCT03997851
View directory record Official record
Conditions
Pruritus
Interventions
Acetaminophen, Carbomer 980
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 25, 2026, 10:22 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

NCT06043323
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate, Prednisone, Diphenhydramine, Acetaminophen
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 25, 2026, 10:22 PM EDT
Completed No phase listed Observational

The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study

NCT00446862
View directory record Official record
Conditions
Fabry Disease, Proteinuria
Interventions
enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions

NCT01712113
View directory record Official record
Conditions
Hypertension
Interventions
Irbesartan, Avapro
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome

NCT00723801
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Atenolol, Losartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 25, 2026, 10:22 PM EDT
Withdrawn Not applicable Interventional

Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department

NCT00657228
View directory record Official record
Conditions
Anaphylaxis
Interventions
Intravenous heparin, Saline
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 25, 2026, 10:22 PM EDT
Terminated Phase 2 Interventional Results available

Losartan for the Treatment of Pediatric NAFLD

NCT03467217
View directory record Official record
Conditions
NAFLD - Nonalcoholic Fatty Liver Disease
Interventions
Losartan potassium, Placebo losartan capsule
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 4 Interventional Results available

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

NCT00926289
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan, Hydrochlorothiazide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
18
States / cities
Athens, Alabama • Mobile, Alabama • Lomita, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 25, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

NCT05232825
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV, Diphenhydramine IV, Dexamethasone given orally, Desloratadine given orally
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Maitland, Florida • Tampa, Florida • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 25, 2026, 10:22 PM EDT